Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow
Breast cancer cells frequently home to the bone marrow, where they may enter a dormant state before forming a bone metastasis. Several members of the interleukin-6 (IL-6) cytokine family are implicated in breast cancer bone colonization, but the role for the IL-6 cytokine leukaemia inhibitory factor (LIF) in this process is unknown. We tested the hypothesis that LIF provides a pro-dormancy signal to breast cancer cells in the bone. In breast cancer patients, LIF receptor (LIFR) levels are lower with bone metastases and are significantly and inversely correlated with patient outcome and hypoxia gene activity. Hypoxia also reduces the LIFR:STAT3:SOCS3 signalling pathway in breast cancer cells. Loss of the LIFR or STAT3 enables otherwise dormant breast cancer cells to downregulate dormancy-, quiescence-and cancer stem cell-associated genes, and to proliferate in and specifically colonize the bone, suggesting that LIFR:STAT3 signalling confers a dormancy phenotype in breast cancer cells disseminated to bone.
Breast cancer cells disseminated to the bone marrow possess the ability to remain in a dormant state for years before emerging as a clinically detectable bone metastasis 1 . The mechanisms enabling tumour cells to emerge from dormancy are poorly understood, but there is increasing evidence that tumour-stromal interactions, and the osteoblast 2,3 , perivascular 4 and perisinusoidal 5 niche are critical mediators of tumour cell dormancy and bone colonization. Hypoxia, or very low oxygen tensions, has also been implicated in modulating tumour dormancy 6 , but the role for hypoxia in tumour cell dormancy in the bone has not been investigated 7 .
Several members of the interleukin-6 (IL-6) family of cytokines, such as IL-6 and oncostatin M (OSM), have been demonstrated to promote breast cancer colonization of the bone marrow 8, 9 . The leukaemia inhibitory factor (LIF) receptor (LIFR), whose ligand LIF also belongs to the IL-6 family of cytokines, was recently identified as a breast tumour suppressor and lung metastasis suppressor 10, 11 . Previous correlations between LIF and LIFR expression in breast cancer cell lines capable of colonizing the bone 12 suggest that the LIF signalling pathway may play a key role in tumour establishment in bone.
RESULTS

LIFR is downregulated in patients with bone metastases
We first investigated LIFR expression in primary tumours of breast cancer patients who were predicted to have a poor prognosis 13 , and found that LIFR messenger RNA levels were significantly lower in those patients with bone metastases (Fig. 1a ). In this same patient data set 14 , signal transducer and activator 3 (STAT3) mRNA levels were significantly lower in breast cancer patients with a poor prognosis compared with those with a good prognosis ( Fig. 1b ). STAT3 is a mediator of downstream LIF:LIFR signalling and can repress or activate target genes, including suppressor of cytokine signalling 3 (SOCS3), which is activated by LIF and can negatively regulate STAT3 15 . In patients with invasive breast carcinoma, STAT3 mRNA levels positively correlated with SOCS3 mRNA levels ( Fig. 1c ), suggesting that this signalling axis may be important in patient outcome. Indeed, patients with mRNA downregulation of LIFR:STAT3:SOCS3 genes had significantly reduced overall survival ( Fig. 1d and Supplementary Fig. 1a-c) , and there was a significant co-occurrence of alterations (amplification, homozygous deletion, mutation or mRNA expression changes) within the LIFR and STAT3 genes, as well as STAT3 and SOCS3 ( Supplementary Fig. 1d ). LIFR and SOCS3 mRNA levels were significantly lower in breast cancer patients with the luminal B subtype, which is the tumour type that most frequently metastasizes to bone 16 , as well as in basal-like (LIFR only), and HER2-enriched tumour types, which are more aggressive subtypes (Fig. 1e,f ), suggesting that LIFR and SOCS3 are downregulated in patients most likely to develop bone metastases. Supplementary  Fig. 9 . Graphs represent mean per group and error bars represent s.e.m. * P < 0.05, * * P < 0.01 and * * * P < 0.001.
Hypoxia represses the LIFR in breast cancer cells and is negatively correlated with LIFR in patients
Since alterations in the LIFR result in significantly worse patient survival and it has been demonstrated that hypoxia in breast tumours is linked to poor patient survival [17] [18] [19] [20] , we hypothesized that hypoxia may downregulate the LIFR in breast cancer cells and signal cells to exit dormancy. Analysis of invasive breast carcinoma patients from The Cancer Genome Atlas (TCGA) revealed that as hypoxia gene activity increases 21 , LIFR mRNA levels are significantly reduced ( Fig. 1g ), indicating that hypoxia may be a mechanism by which breast cancer cells downregulate the LIFR. Hypoxia has been previously identified as a regulator of the LIFR in embryonic stem cells 22 . To investigate this relationship, MCF7 human breast cancer cells were cultured in hypoxic conditions (0.5% O 2 ), and LIFR mRNA and protein levels, and SOCS3 mRNA levels, were reduced ( Fig. 1h-j and Supplementary  Fig. 2a, shRNA3 ), indicating that hypoxia downregulates the entire LIFR:STAT3:SOCS3 signalling pathway. PGK1 mRNA levels were used as a positive control for activation of hypoxia-inducible signalling ( Supplementary Fig. 2b ). The breast cancer cell line SUM159, with known low metastatic potential for the lungs, showed a reduction Supplementary Fig. 9 . Graphs represent the mean per group and error bars represent the standard error of the mean (s.e.m.). * P < 0.05, * * P < 0.01, and * * * P < 0.001. #P < 0.05 and ##P < 0.01 versus 0 mM Nx. in LIFR mRNA levels similar to MCF7 cells following culture in hypoxia ( Supplementary Fig. 2c ). A similar effect on LIFR and SOCS3 mRNA levels was observed when MCF7 cells were treated with dimethyloxalylglycine (DMOG), a pharmacological activator of HIF signalling ( Fig. 1k ,l).
Hypoxic regulation of the LIFR is HIF-independent
Although hypoxia and DMOG were able to induce LIFR downregulation, we found that neither HIF1α nor HIF2α was needed for hypoxic repression of the LIFR (Fig. 2a ). We also identified six hypoxia-responsive elements (HREs), and one reverse HRE 23 , in the proximal promoter of the LIFR. Mutation of activating HREs and the reverse HRE, or the reverse HRE alone, indicated that these regions of the promoter are not required for hypoxic repression of the LIFR (Fig. 2b) . These data suggest a HIF-independent, but DMOGinducible mechanism for hypoxic repression of LIFR transcription. It has previously been reported that DMOG can promote methylation on histone H3, and thus induce gene repression through stimulation of histone methyltransferases and inhibition of histone demethylases 24 . Interestingly, DMOG can promote repression of some genes while still activating HIF target genes 24 , suggesting that DMOG could inhibit LIFR through HIF-independent effects. Since we found that the histone methyltransferase SETDB1 and histone deacetylase HDAC2 both bind to the LIFR and make modifications on histone H3 on Lys9 (Fig. 2c ), and SETDB1 is hypoxia-inducible 25 , we evaluated these enzymes in the hypoxic repression of the LIFR in breast cancer cells. Knockdown of either gene alone or in combination was not sufficient to rescue downregulation of the LIFR in hypoxia ( Fig. 2d ). However, it is well documented that HDACs and histone methyltransferases possess compensatory functions 26 . Therefore, we used the pan-HDAC inhibitor valproic acid (VPA) 27 , which enhanced histone H3 acetylation in MCF7 cells in vitro ( Fig. 2e) , and significantly increased LIFR and SOCS3 mRNA levels in hypoxia ( Fig. 2f,g ), suggesting that HDAC inhibition enhances LIFR:STAT3:SOCS3 signalling.
We also investigated whether the LIFR was methylated at the DNA level in patients with breast carcinoma, and whether increased LIFR methylation may relate to poor patient outcome. Analysis of the invasive breast carcinoma cohort from TCGA revealed that LIFR and STAT3 mRNA levels significantly decrease as LIFR DNA methylation increases ( Supplementary Fig. 2d,e ), suggesting that methylation, or repression, of the LIFR gene may lead to repression of STAT3 in patients. LIFR mRNA levels are significantly lower in breast cancer patients who have recurred/progressed ( Supplementary Fig. 2f Supplementary Table 1 and unprocessed original scans of blots are shown in Supplementary Fig. 9 . The mean is indicated on the graph. Graphs represent the mean per group and error bars represent the s.e.m. Fig. 2g ), suggesting that LIFR DNA methylation is directly related to a negative patient outcome. Since up to 70% of breast cancer patients who succumb to disease present with bone metastases on autopsy 7 , we hypothesize that many of those patients who recurred/progressed will also harbour bone metastases.
LIF inhibits breast cancer cell growth in tumour cells known to lie dormant in bone
Since cells of the osteoblast lineage and bone marrow stromal cells produce LIF [28] [29] [30] [31] [32] , we hypothesized that LIF may act as an inhibitory signal to breast cancer cells known to home to the bone marrow.
MCF7 cells have been shown to home to the bone marrow following intracardiac 33 and intrailiac inoculation 3 , where they induce limited bone destruction, thus acting as dormant tumour cells in the bone marrow, similar to their dormant phenotype in the lungs following intravenous inoculation 34 . MCF7 cells were growth inhibited in response to recombinant LIF ( Supplementary Fig. 3a ), while bone metastatic variants of MDA-MB-231 (MDA-MB-231b 35, 36 ) and 4T1 cells (4T1BM2 37 ) were growth resistant to recombinant LIF in vitro ( Supplementary Fig. 3b ,c). Likewise, low doses of LIF induced SOCS3 expression in MCF7 ( Supplementary Fig. 3d ), but not MDA-MB-231b cells ( Supplementary Fig. 3e ), indicating that cells such as the Supplementary Fig. 9 . Graphs represent the mean per group and error bars represent the s.e.m. * P < 0.05, * * P < 0.01, * * * P < 0.001 and * * * * P < 0.0001.
MCF7s that home to the bone and essentially lie dormant are sensitive to LIF.
Breast cancer cells with low metastatic potential maintain a functional LIFR
Human breast and mouse mammary carcinoma cell lines with low metastatic potential, MCF7, SUM159, PyMT, and D2.0R mouse mammary carcinoma cells, all showed abundant expression of the LIFR at the protein level, and rapidly phosphorylated STAT3 and induced SOCS3 transcription in response to recombinant oncostatin M (OSM) or recombinant LIF ( Fig. 3a,b ,e,f and Supplementary Fig. 4a-d) , indicating that both signalling pathways are functional. Conversely, the MDA-MB-231b, 4T1BM2 and D2A1 mouse mammary carcinoma cells, which grow aggressively in metastatic sites, were unresponsive to recombinant LIF, but maintained a STAT3:SOCS3 response to recombinant OSM ( Fig. 3c,d ,g,h and Supplementary Fig. 4e ,f), suggesting that loss of the LIFR:STAT3 signalling pathway may confer loss of dormancy.
We also compared the 4T1 and MDA-MB-231 parental cell lines to their bone metastatic variants (4T1BM2 and MDA-MB-231b cell lines). In 4T1 parental cells, Lifr was semi-functional in terms of inducing Stat3 phosphorylation in response to Lif ( Supplementary  Fig. 4g ), but not Socs3 mRNA induction ( Supplementary Fig. 4h ). In MDA-MB-231 parental cells multiple glycosylated forms of the LIFR were expressed ( Supplementary Fig. 4i ), but STAT3 and SOCS3 signalling were not activated downstream ( Supplementary Fig. 4i,j) . It is important to note that 4T1 and MDA-MB-231 parental lines will readily grow in and colonize the bone, and therefore may possess other mechanisms or mutations that can promote bone invasion independent of the effects of the LIFR. Supplementary Fig. 8a) 
Loss of the LIFR enhances invasion and downregulates dormancy, quiescence and cancer stem cell-associated genes
To determine the impact of LIFR expression on MCF7 tumour cell behaviour, we analysed MCF7 control (MCF7 non-silencing control; MCF7NSC) and MCF7 cells in which LIFR was functionally knocked down (MCF7-LIFR-shRNA3; Supplementary Figs 2a and 5a,b) . LIFR knockdown did not alter proliferation in vitro or in the mammary fat pad in vivo ( Supplementary Fig. 5c,d) , but increased MCF7 migration and invasion in 3D cultures ( Supplementary Fig. 5e,f) , consistent with the phenotype of LIFR knockdown in SUM159 cells 10 . These data suggest that loss of LIFR signalling disrupts autocrine LIF signalling to downstream targets and promotes tumour cell migration and invasion.
We next identified key dormancy and quiescence genes validated across tumour models ( Supplementary Fig. 6a ) [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] , and tested their expression in our LIFR knockdown model. Loss of LIFR signalling in MCF7 cells resulted in lower mRNA levels in 6 out of 12 genes associated with a dormancy/quiescence phenotype, including thrombospondin-1 (TSP1) 38, 44 , tropomyosin-1 (TPM1) 38, 44 , transforming growth factor-β2 (TGF-β2) 39, 44 , prolyl 4 hydroxylase α-1 (P4HA1) 38, 44 , 43 and SELENBP1 45 (Fig. 4a ), suggesting that intact LIFR signalling regulates genes involved in dormancy. A similar, but less dramatic reduction in dormancy/quiescence genes was detected in SUM159-LIFR-shRNA cells ( Fig. 4b and Supplementary Fig. 6b ). LIFR knockdown in MCF7 cells also resulted in lower p53 38, 41, 46 protein levels, and greater c-MYC 42, 45 and pSRC 34, 40 (Y527) protein levels (Fig. 4c) , consistent with an exit from dormancy [40] [41] [42] .
Dormant or quiescent cancer cells may adopt a cancer stem cell phenotype 49 , and thus we evaluated a number of cancer stem cell-associated genes 45, 50 . We found a dramatic downregulation of NOTCH1, Caspase-3 (CASP3 (Sca1)), TERT and SOX2 in MCF7-LIFR-shRNA cells (Fig. 4d ), and all genes were mildly reduced in SUM159-LIFR-shRNA cells ( Fig. 4e ), suggesting that LIFR signalling may maintain both a dormant and cancer stem cell phenotype. However, LIFR deletion did not alter the percentage of MCF7 cells exhibiting the cancer stem cell CD44 Hi /CD24 Lo marker phenotype 51 (Fig. 4f) .
We also confirmed that LIFR effects on patient outcome and tumour dormancy were not mediated via downstream PI(3)K:mTOR 52 or MAPK 53 signalling cascades ( Supplementary Fig. 7a-h) .
PTHrP overexpression ablates LIFR signalling in MCF7 cells
Parathyroid hormone-related protein (PTHrP) is a secreted factor required for breast tumour-induced bone destruction 35 . Studies indicate that direct inhibition of PTHrP shortly after tumour inoculation is beneficial in blocking tumour-induced osteolysis 35, 54 . When MCF7 cells are forced to overexpress PTHrP (Fig. 5a ), these cells induce extensive bone destruction, and MCF7 cells no longer reside in a dormant state 33 . We found that both LIFR and SOCS3 mRNA levels and LIFR protein were significantly repressed in MCF7 cells overexpressing PTHrP (Fig. 5b,c) . LIF stimulation of STAT3 phosphorylation ( Fig. 5c ) and SOCS3 induction ( Fig. 5d ) was dampened in MCF7PTHrP-overexpressing cells, indicating that PTHrP negatively regulates LIFR:STAT3:SOCS3. Interestingly, MCF7-LIFR-shRNA cells expressed twofold higher levels of PTHrP (Fig. 5e ), suggesting a potential regulatory loop between LIFR and PTHrP signalling. As for LIFR knockdown in MCF7 cells, we observed significant downregulation of dormancy-, quiescence-, and cancer stem cell-associated genes in MCF7 cells overexpressing PTHrP (Fig. 5f,g) . Thus, repression of the LIFR, either directly or perhaps through PTHrP overexpression, impacts the expression of dormancyassociated genes.
Valproic acid stimulates dormancy-and cancer stem cell-associated genes
Since valproic acid increases LIFR mRNA levels in MCF7 cells (Fig. 2f ), we hypothesized that valproic acid may enhance expression of genes associated with dormancy, quiescence and a cancer stem cell phenotype. Indeed, valproic acid significantly stimulated 9 out of 12 dormancy-and quiescence-associated genes, and 5 out of 6 cancer stem cell-associated genes (Fig. 5h,i) . These data suggest that LIFR expression has a corresponding effect on dormancy-and cancer stem cell-associated genes.
Loss of LIFR in MCF7 cells induces osteolytic bone destruction
Since loss of LIFR signalling resulted in a decrease in genes associated with dormancy, we investigated whether deletion of LIFR increases MCF7 colonization and growth in the bone marrow following intracardiac inoculation. MCF7 cells in the bone marrow were identified in 6 of 7 MCF7NSC and 7 of 7 MCF7-LIFR-shRNA tumourbearing mouse tibiae by human keratin staining (Fig. 6a ). As expected, MCF7NSC cells did disseminate to the bone, and we observed limited bone destruction. In contrast, MCF7-LIFR-shRNA cells disseminated to the bone and induced significant bone destruction as indicated by lesion area and lesion number on X-ray analysis ( Fig. 6b-d ). Histological analysis also revealed significantly lower bone volume in MCF7-LIFR-shRNA tumour-bearing mice (Fig. 6e,f) , which may be attributable to the significantly greater number of osteoclasts lining the bone surface in MCF7-LIFR-shRNA tumour-bearing bones (Fig. 6g,h) .
Pockets of tumour infiltration co-localize with strong staining for a hypoxia marker
MCF7NSC tumour infiltration coincided with strong staining for the hypoxia probe pimonidazole in the bone marrow, while areas where MCF7NSC cells appeared to lie dormant in the bone without inducing bone destruction stained weakly for pimonidazole within the same limb (Fig. 6i , lower left and lower right). In contrast, MCF7-LIFR-shRNA tumours infiltrated the bone regardless of pimonidazole staining intensity (Fig. 6i, upper right) . These data are consistent with a mechanism by which hypoxia may promote outgrowth of indolent breast cancer cells disseminated to the bone marrow.
Loss of LIFR promotes MCF7 proliferation within the bone marrow
We found that the majority of MCF7NSC cells did not stain for Ki67 (a proliferative marker) while MCF7-LIFR-shRNA cells stained for Ki67 within the bone marrow (Fig. 6j,k and Supplementary Fig. 8a) . A small percentage of MCF7 tumour cells slowly invaded the bone over time and stained positive for Ki67. This is consistent with the gradual increase in osteolysis detected by radiography within MCF7 control tumour-bearing mice over the course of 10 weeks. However, the numbers of these cells still remained less than the Ki67-positive MCF7-LIFR-shRNA tumour cells in the bone marrow ( Fig. 6j,k) . For the most part, MCF7 control cells appeared quiescent in vivo. These data support the idea of intrinsic differences in these cells after dissemination to the bone marrow.
We also stained for pimonidazole and found that MCF7NSC cells, although for the most part Ki67-negative, can be found in pimo-positive regions (Fig. 6i,j) . Interestingly, there was pronounced pimonidazole staining along the tumour-bone interface in both MCF7NSC and MCF7-LIFR-shRNA tumour-bearing limbs ( Supplementary Fig. 8b ), suggesting that this region may be where the tumour cells are most likely to become invasive. Supplementary Table 1 . Unprocessed original scans of blots are shown in Supplementary Fig. 9 . Graphs represent the mean per group and error bars represent the s.e.m. * P < 0.05 and * * P < 0.01.
Many factors that have been found to regulate dormancy act in a tissue-specific manner 4, 39, 55, 56 . We confirmed that MCF7-LIFR-shRNA cells colonize the lung at a similar rate to MCF7NSC cells ( Supplementary Fig. 8c,d) . This corroborates patient data derived from Minn et al. 14 , which show no significant difference in LIFR mRNA levels in patients with a poor prognosis who developed lung metastases versus those with no lung metastases ( Supplementary Fig. 8e ), and is in contrast to previously published data showing a dramatic role for LIFR in suppressing breast cancer lung colonization 10 . Since the previously published study used oestrogenreceptor (ER)-negative human breast cancer cells, and the MCF7 cells in our study are ER positive, we propose the difference in lung colonization may be due to ER expression.
Loss of STAT3 signalling in breast cancer cells mimics loss of LIFR in vivo
To determine whether LIFR effects on tumour cell dormancy in bone are mediated through STAT3 signalling, we inoculated MCF7 cells that had stable STAT3 knockdown ( Fig. 7a,b ; clones 641817 and 376016) by intracardiac injection. Loss of STAT3 in MCF7 cells induced significantly greater bone destruction in vivo with both clones (Fig. 7c-e ), similar to MCF7 cells lacking the LIFR. These data indicate that STAT3 acting downstream of the LIFR may be an important mediator of tumour-induced osteolysis and MCF7 exit from dormancy.
Inhibiting STAT3 signalling downregulates dormancy-associated genes
Since STAT3 is a key mediator of LIFR signalling, we investigated STAT3 phosphorylation in MCF7-LIFR-shRNA tumour cells by immunocytochemistry and found that nuclear staining was reduced (Fig. 8a,b) . We next inhibited STAT3/SOCS3 by treatment with a small-molecule STAT3 inhibitor (ML116, which we termed Stat3i; Supplementary Fig. 8f-h Multiple t-tests with Holm-Sidak method. n = 3 biological replicates, one each from three independent experiments. (g) Flow chart indicating that hypoxia differentially regulates LIFR and PTHrP, which signal via STAT3 and SOCS3 to regulate dormancy-associated genes and thus influence bone colonization. (h) Working model for LIFR:STAT3 signalling in disseminated breast cancer cells transitioning from a dormant to invasive phenotype in strongly hypoxic regions of the bone marrow. Graphs represent the mean per group and error bars represent the s.e.m. * P < 0.05, * * P < 0.01, * * * P < 0.001, and * * * * P < 0.0001. (Fig. 8c ), and 2 out of 4 of the cancer stem cell genes that were downregulated with LIFR knockdown (Fig. 8d ). Stat3i treatment also significantly downregulated mRNA levels of all 6 of the remaining dormancy genes that were not regulated via LIFR signalling ( Supplementary Fig. 8i ). A similar, but modest effect on dormancy and cancer stem cell-associated genes was observed with siRNA against SOCS3 in MCF7 cells (Fig. 8e,f and Supplementary Fig. 8j ) and SUM159 cells ( Supplementary Fig. 8k,l) .
DISCUSSION
We conclude from our analysis of LIFR expression across all breast cancer cell lines that breast cancer cells with low metastatic potential, either to the lung (MCF7, D2.0R, PyMT) or to the bone (MCF7), express a functional LIFR and are LIF responsive. In contrast, breast cancer cells that aggressively colonize the lung (D2A1) or bone (MDA-MB-231b, 4T1BM2) lack a functional LIFR and do not respond to LIF in vitro. Interestingly, the 4T1BM2 and D2A1 cells expressed very low levels of the Lifr (Fig. 3d and Supplementary Fig. 4e ), while MDA-MB-231b cells expressed high levels of the LIFR (Fig. 3c) , although all three cell lines are highly metastatic. We suspect that the LIFR is inactive in MDA-MB-231b tumour cells, since they do not respond to LIF in vitro. Together these data suggest that breast cancer cells with high metastatic potential, which readily home to and colonize the bone, are unable to respond to paracrine LIF produced in the bone by marrow cells and the osteoblast niche.
Our findings indicate that LIFR is important for maintaining tumour cells in a dormant state. In support of this hypothesis, it has previously been reported that LIF and LIFR mRNA levels are elevated in dormant versus proliferative squamous cell carcinoma cells (supplemental expression data) 57 and that LIFR levels are elevated in cells in a G0 (non-proliferative) state (supplemental expression data) 45 . STAT3 has also been identified as a dormancy-associated gene in ER-positive breast cancer cells, which are reported to have higher dormancy signature scores than ER-negative breast cancer cells 38 .
LIFR signalling has been found to negatively regulate the stem cell pool 58 , and our data in tumour cells are in contrast to these findings. The physiological role for LIF is to maintain a stem-like state 59 , and thus our data are consistent with a role for LIFR signalling in maintaining a less differentiated cell phenotype. It has also been shown that cells with high metastatic potential (for example, MDA-MB-231 cells) express higher levels of LIF 60 , which may enable these cells to secrete paracrine LIF within the bone marrow to drive LIFR signalling in other cell types and prevent differentiation. It is possible that all of the effects of LIF:LIFR signalling in MDA-MB-231 cells are mediated via AKT/mTOR signalling as previously reported 60 . However, we did not focus on this signalling pathway since it was not implicated in dormancy regulation. Importantly, while overexpression of LIF did result in significantly reduced relapse-free survival 60 , greater than 75% of patients overexpressing LIF in their tumours remained disease-free by 10 years out, compared with 0% overall survival in patients with LIFR downregulation at this same time point (Fig. 1d ). This suggests that the loss of a functional LIFR may be critical for patient outcome and fits with the less dramatic effects of LIFR/AKT/mTOR signalling on overall survival that we found in patient data. Hypoxia has also been shown to induce LIF in colorectal carcinoma cell lines 61 , but the status of the LIFR is not clear in those cell lines, and thus what effect elevated LIF may have on autocrine signalling is unknown. It is possible that the HIF2α-driven upregulation of LIF in those cells may also activate an alternative pathway to STAT3 such as AKT/mTOR. Our data suggest that activation of alternative pathways downstream of the LIFR may have a dramatically different impact on patient survival.
We observed an increase in pimonidazole staining along the tumour-bone interface, suggesting that this may be where tumour cells are most likely to become invasive. Alternatively, the osteogenic niche may promote the outgrowth of early disseminated tumour cells in the bone marrow 3 and support the homing of disseminated proliferative human breast cancer cells 5 . Furthermore, the presence of tumour cells in this niche may be driving down oxygen tensions due to localized increased oxygen consumption. The occasional Ki67-positive cells found in MCF7NSC samples may have encountered the hypoxic microenvironment and have shut down their dormancy machinery to become proliferative; however, our current technologies do not enable us to determine whether hypoxia is driving that process through LIFR.
Our data also indicate that STAT3 may be a key mediator of the LIFR-induced dormancy phenotype. However, STAT3 may play a diminished role in the LIFR-mediated effects on cancer stem cell gene expression, since many of those genes were unaltered or stimulated by STAT3 inhibition. Interestingly, treatment with the small-molecule inhibitor Stat3i also significantly downregulated mRNA levels of all 6 of the remaining dormancy genes that were not regulated by LIFR signalling ( Supplementary Fig. 8i ), suggesting that STAT3 may be a major mediator of tumour dormancy and that these effects are not restricted to a LIFR-mediated mechanism. While STAT3 inhibitors are generally used as anticancer agents 62 , our data suggest that loss of STAT3 signalling stimulates tumour cells to exit dormancy. Thus, STAT3 inhibition in patients with disseminated tumour cells may be detrimental to patient outcome and may in part explain why STAT3 inhibitors have failed to produce a positive outcome in clinical trials for breast cancer 62 .
In summary, LIFR:STAT3:SOCS3 signalling in disseminated breast cancer cells confers a dormancy phenotype through maintenance of STAT3 signalling in response to LIF. In regions of extremely low oxygen tensions within the bone marrow, tumour cells become invasive through downregulation of STAT3 and possibly SOCS3 signalling. These data provide a mechanism by which tumour cells may be directed to spontaneously exit dormancy by the bone microenvironment and indicate that stimulating the LIFR:STAT3:SOCS3 signalling pathway in breast cancer cells may prevent the outgrowth of indolent tumour cells disseminated to the marrow.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3408 METHODS Cell culture and reagents. Cells. Human MCF7 and MDA-MB-231 breast cancer cells and 4T1 mouse mammary carcinoma cells were obtained from ATCC and cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin (P/S). Human SUM159 breast cancer cells were a gift from the Rutgers Cancer Institute of New Jersey and were cultured in Ham's F12 medium supplemented with 5% FBS, 5 µg ml −1 insulin and 1 µg ml −1 hydrocortisone. Mouse mammary carcinoma cell lines D2A1 and D2.0R were a gift from J. Green at the National Cancer Institute. PyMT-derived tumour cells were established in R. Anderson's laboratory. Human MDA-MB-231b bone metastatic cells were established from the original bone clone made by the Mundy laboratory, and passaged in bone periodically to maintain bone metastatic phenotype 35, 36 . 4T1BM2 bone metastatic mouse mammary carcinoma cells 37 were a gift from N. Pouliot at the Peter MacCallum Cancer Centre. MCF7pcDNA-and MCF7PTHrP-overexpressing cells 33 were established in J. Martin's laboratory at St. Vincent's Institute of Medical Research and were a gift from T. Guise at Indiana University. All cell lines, except SUM159 human breast cancer cells, were cultured in DMEM supplemented with 10% FBS and P/S. No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample. MCF7 cells were re-authenticated by ATCC; none of the remaining cell lines have been re-authenticated. The MCF7 cells were tested for mycoplasma contamination; none of the remaining cell lines have been tested for mycoplasma contamination.
shRNA and siRNA. GIPZ lentiviral LIFR-and STAT3-targeting human shRNAs were purchased from Open Biosystems (catalogue numbers in parentheses). -200223545) . GIPZ vectors were transfected into 293T cells using Lipofectamine Plus (Life Technologies) to generate lentivirus, which was then transferred onto MCF7 or SUM159 cells. Breast cancer cells were selected for 6 days in 1 µg ml −1 puromycin and evaluated for knockdown at the protein and mRNA level. ON-TARGETplus SMARTpool siRNAs for HIF1A (L-004018-00), EPAS1 (HIF2A) (M-004814-01), SETDB1 (L-020070-00), HDAC2 (L-003495-02) and SOCS3 (L-004299-00) were purchased from Dharmacon/GE Healthcare (catalogue numbers in parentheses) along with ON-TARGETplus SMARTpool siControl (D-001810-10-20) and transfected into MCF7 or SUM159 cells using DharmaFECT 1 transfection reagent (Dharmacon/GE Healthcare).
Stat3 small-molecule inhibitor. The STAT3 inhibitor probe referred to as Stat3i in the text was provided by W. Roush at The Scripps Research Institute (Scripps Florida) and its Scripps probe ID is ML116. The inhibitor is a thienopyrimidine scaffold: 4-(4-benzylpiperidin-1-yl)thieno [2,3-d] pyrimidine and the PubChem ID is 2100018. The probe was identified in a high-throughput screen for STAT3 inhibitors and was selected for its specificity for STAT3 over STAT1 and NFκB. Details of the screen can be found at the Scripps Research Institute website (http://mlpcn.florida.scripps.edu/ index.php/probes/probe-reports.html).
To determine whether ML116 (Stat3i) may be a biologically active inhibitor, we used receptor-based virtual screening and molecular docking to determine whether Stat3i will specifically bind and inhibit the activity of STAT3. We obtained the crystallized three-dimensional structure of a STAT3 monomer from the Protein Data Bank database and we were able to confirm docking and molecular interactions between STAT3 and ML116, with ML116 virtually docking adjacent to the DNAbinding groove of the STAT3 monomer with a docking score of −7.3 (considered favourable binding affinity), suggesting disruption of STAT3 and DNA binding.
Recombinant proteins. Recombinant human LIF (R&D Systems), human oncostatin M (R&D Systems), mouse LIF (Miltenyi Biotec), mouse oncostatin M (R&D Systems) and human TGF-β1 (R&D Systems) were reconstituted in PBS + 0.1% bovine serum albumin (BSA) at 10-25 µg ml −1 and aliquoted for storage at −80 • C. For all experiments, mouse recombinant proteins were used on mouse cell lines, and human recombinant proteins were used on human cell lines, with the exception of human TGF-β1, which was used on all cell lines since TGF-β1 maintains approximately 99% sequence homology between human and mouse species 63 . Before cytokine treatment cells were serum starved in 2% FBS overnight and cytokine treatment was made up in media containing 2% FBS.
Hypoxia. For hypoxia experiments, cells were seeded at 1 × 10 5 cells per well in normoxia, allowed to settle overnight, and placed into a hypoxia (0.5% O 2 ) chamber (Invivo 2 Hypoxia Workstation 400) the following day for 24-48 h, as indicated in the figure legends. Cells were harvested in situ for RNA with TRIzol (Life Technologies) or for protein in RIPA lysis buffer supplemented with protease and phosphatase inhibitors (Roche). For siRNA-transfected cells, transfection was performed in normoxia and cells incubated overnight before being transferred to the hypoxia chamber.
DMOG treatment. Cells were seeded at 2.5 × 10 5 cells per well and incubated overnight. Cells were treated with 1 mM DMOG or an equal volume of vehicle (water) for 16 h in full serum conditions and harvested for RNA with TRIzol (Life Technologies) or for protein in RIPA lysis buffer supplemented with protease and phosphatase inhibitors (Roche).
Valproic acid (VPA) treatment. Cells were seeded at 4 × 10 5 cells per well and valproic acid (VPA, Sigma-Aldrich) treatment was performed in DMEM+10% FBS. Addition of VPA did not alter the pH of the media, even at the highest dose of 10 mM (tested with pH strips). For experiments in which tumour cells were transfected with the LIFR WT promoter before treatment, VPA was added to the transfection media. For experiments in which mRNA levels were evaluated following culture in normoxia or hypoxia ± VPA treatment, VPA was added to the cells in normoxia and cells were moved into hypoxia one hour later. PI(3)K (BEZ235) and ERK1/2 (AZD6244) inhibitors. MCF7 cells were seeded at 4 × 10 5 cells per well in 6-well cluster dishes and treated the following day with either vehicle (water), 10 nM, 100 nM or 1,000 nM BEZ235 or vehicle (dimethylsulfoxide), 0.1 µM, 1 µM or 10 µM AZD6244 for 24 h in full serum conditions. Cells were harvested at 24 h for RNA in TRIzol and processed for qPCR. For western analysis, cells were seeded at 1 × 10 6 in 10 cm dishes and treated the following day at the same concentrations as above and harvested for protein in RIPA buffer after 24 h.
XTT assay. Cells were seeded at 2 × 10 4 cells per well in triplicate into 96-well plates and settled after 2 h in culture. Plating medium was removed and replaced with DMEM+2% FBS and either vehicle (PBS), recombinant LIF (50 ng ml −1 ) or recombinant TGF-β (5 ng ml −1 ). Transforming growth factor-β1 (TGF-β1) was used as a positive control, since breast cancer cells are growth inhibited by TGF-β1 early in tumour progression, which can also be detected in vitro 64 . Media and treatments were replenished daily while cells grew in culture. At the end point, cells were incubated in serum-phenol-red-free DMEM with PMS and XTT sodium salt for 2-4 h until colour change and measured for absorbance at 450 nm using a Synergy H1-mono plate reader (Biotek).
Migration and invasion assays. Migration. Cells were seeded at 1 × 10 6 cells per well into 6-well plates and settled for 24 h for migration (scratch) assays. Three vertical scratches were made through the cell layer using marker guidelines drawn on the bottom of the plate to ensure consistency in imaging time points. Bright-field images were captured at 0 and 24 h after the scratch was made and wound closure was quantified as a percentage of the initial wound area using Image-Pro software.
Invasion/3D cultures. Cells were seeded at 12.5 × 10 3 cells per well into 48-well plates in quadruplicate in a 3:1 ratio with rat collagen type I (BD Biosciences) and allowed to polymerize at room temperature for 30 min. Plates were incubated at 37 • C for 4 h and then 0.5 ml medium was added to each well. Medium was changed every 1-2 days and bright-field images were acquired using an inverted microscope.
Immunostaining. Cells were seeded into 4-well chamber slides (Biotek) at 5 × 10 3 cells per chamber and incubated overnight. Cells were fixed in 10% formalin and permeabilized in 0.25% Triton-X in PBS. Cells were stained sequentially with a primary antibody against pStat3 Tyr705 (Cell Signaling, clone D3A7 XP, catalogue number 9145, 1:50), secondary antibody biotinylated goat anti-rabbit, and streptavidin-Texas red, and counterstained with DAPI. Fluorescence images were acquired on a Leica CTR6000 microscope (Leica) and Hamamatsu digital camera (C11440) using LAS X software (Leica) and overlaid using ImageJ software.
LIFR promoter construct and activity. The human LIFR sequence was identified using the UCSC Genome Browser December 2013 Assembly (most recent data set available). The FASTA sequence for LIFR transcript variant 1 coding sequence was obtained and BLASTed (NCBI) against mRNA from NCBI LIFR variant 1, with 100% matching sequence. The transcription start site was identified and 2 kb of the proximal promoter scanned for hypoxia-responsive elements (HREs) and reverse HREs (rHRE) using consensus sequences CACGT, GCGTG, ACGTG, CGTG for HREs and TGCAC for rHREs. Six HREs and one rHRE were identified within 1.3 kb upstream of the LIFR transcription start site (3 proximal to the transcription start site and 3 distal). There were no HREs identified between ∼1.3-2 kb upstream of the transcription start site. The consensus sequence ACGTG was the only HRE not found in the LIFR promoter. The following constructs were synthesized: LIFR wildtype promoter construct, LIFR construct with all HREs and the rHRE mutated, and LIFR construct with only the rHRE mutated. All constructs were synthesized and cloned into the pGL3 basic vector by GenScript. Cells transfected with promoter constructs were harvested in 1× passive lysis buffer and assessed for activity after 48 h in normoxic and hypoxic conditions (72 h after transfection) using the Bright-Glo/Renilla luciferase assay system (Promega) per the manufacturer's instructions. Plates were read using a Synergy H1-mono plate reader (Biotek).
Western blotting. Cells grown in a monolayer were rinsed with 1× PBS and harvested for protein in RIPA buffer supplemented with a protease and phosphatase inhibitor (Roche). Protein concentration was determined by BCA assay (Thermo Fisher) and 20 µg protein was loaded onto an SDS-PAGE gel in reducing conditions using standard techniques. PVDF membranes were probed with antibodies against LIFR (Santa Cruz Biotechnology, C-19, catalogue number sc-659, 1:1,000), pSTAT3 Tyr705 (Cell Signaling, catalogue number 9131, 1:1,000), STAT3 (Cell Signaling, clone 124H6, catalogue number 9139, 1:1,000), p53 (Invitrogen, clone PAB1801, catalogue number 13-4000, 1:2,000), c-MYC (Cell Signaling, clone D84C12 XP, catalogue number 5605, 1:1,000), pSRC Y527 (Cell Signaling, catalogue number 2105, 1:1,000), SRC (Cell Signaling, clone 36D10, catalogue number 2109, 1:1,000), pAKT Ser473 (Cell Signaling, catalogue number 9271, 1:1,000), AKT (Cell Signaling, catalogue number 9272S, 1:1,000), pERK1/2 Thr202/Tyr204 (Cell Signaling, catalogue number 9101, 1:1,000), ERK1/2 (Cell Signaling, catalogue number 9102, 1:1,000), β-actin (Sigma, clone AC-15, catalogue number A5441, 1:5,000) and vinculin (Millipore, catalogue number AB6039, 1:10,000). All western blots were quantified for adjusted relative density using ImageJ. Adjusted relative density values are listed below each lane. Briefly, blot images were converted to a histogram rendering for each lane and peaks were converted to the relative percentage for each blot. Proteins of interest were then normalized to the relative percentage of the loading control for the respective lane.
In silico analyses. TCGA patient data analysis. The Cancer Genome Atlas cBioPortal was accessed on 24 September 2014, 2 February 2015, 19 February 2015 and 8 January 2016 to determine overall patient survival and the tendency for cooccurrence of LIFR, STAT3 and SOCS3 alterations in the data set for Breast Invasive Carcinoma (http://www.cbioportal.org/study.do?cancer_study_id=brca_tcga_pub# summary; ref. 69 ). LIFR, STAT3 and SOCS3 were entered as the query genes and overall survival and co-expression was provided through the cBioPortal user interface. Data were then downloaded and manually sorted for patients with mRNA downregulation of LIFR, STAT3 and SOCS3. cBioPortal was accessed on 25 March 2016 for survival data for LIFR:PIK3CA:MTOR and LIFR:MAPK3:MAPK1 in the Breast Invasive Carcinoma data set and data were downloaded and manually entered into Prism for survival curve analysis. CBioPortal was accessed on 27 March 2015 to determine whether the hypoxia gene signature from n = 1,104 patients with Breast Invasive Carcinoma (Provisional data set) correlated with the LIFR mRNA expression. First, the hypoxia gene signature from Li et al. 21 and LIFR were entered into the query gene field for cBioPortal downloads on the entry page. The gene expression for each gene across all 1,104 patients was downloaded and saved in Excel format. For each gene in the hypoxia gene signature, the gene expression Statistics and reproducibility. For all studies, n per group is as indicated in the figure legend, bar graphs or numbers on graphs indicate the mean of each group, and error bars indicate standard error of the mean. All graphs and statistical analyses were generated using Prism software (Graphpad). All in vitro and in vivo assays were analysed for statistical significance using Student's unpaired t-test, Mann-Whitney test, multiple t-tests with Holm-Sidak post-test or Welch's correction or ANOVA with Sidak's or Tukey's post-test. See figure legends for detailed statistical analyses for each experiment. For in vitro assays, no statistical method was used to predetermine sample size. In vitro experiments were reproducible, with some variability between biological replicates and experiments. Animal studies were performed one time and included appropriate animal numbers to ensure statistical evaluation. For all analyses P < 0.05 was considered statistically significant, and * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001.
Code availability. Details of the computational pipeline used for the UCSC gene track can be found at https://genome.ucsc.edu/cgi-bin/hgTrackUi?g=knownGene under Methods. Source code used for the SETDB1 and HDAC2 tracks analysis is available at https://sites.google.com/site/anshulkundaje/projects/idr. Details of the H3K9me3 data analysis are available at https://genome.ucsc.edu/cgi-bin/ hgTrackUi?g=wgEncodeSydhHistone under Methods. Data availability. Previously published microarray data sets that we reanalysed here to detect LIFR expression in breast cancer patients with a bone metastasis are available to download as an Excel file in the supplemental data provided by Minn et al. 14 , which includes cross-referenced data for van 't Veer signature, as described above in the in silico section. Previously published human breast invasive carcinoma survival data sets and RNA sequencing data sets that we reanalysed here were reported previously 71, 72 and are available from the TCGA Research Network (http://cancergenome.nih.gov) as described in detail above in the in silico section. Source data for Figs 1h-l, 2a,d, 4a,b,d,e, 5d,e, 6c,d,f,g and 7a,c,d, and Supplementary  Figs 2b, 3a -c, 5b-e, 6b and 8c,d,h have been provided as Supplementary Table 1 . All other data supporting the findings of this study are available from the corresponding author on request.
